Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
A.T.Dinkova Kostova. ( one of the lead investigators in the Star trial ) is a member of the Scientific Advisory Board of Evgen Pharma and a consultant for Aclipse Therapeutics and Vividion Therapeutics.
20 May 2020
News
Roche enters $135m drug discovery deal with Vividion Therapeutics
https://www.pharmaceutical-technology.com/news/roche-vividion-therapeutics-deal/
..........
Published June 2020
KEAP1, a cysteine-based sensor and a drug target for the prevention and treatment of chronic disease
Abstract
Redox imbalance and persistent inflammation are the underlying causes of most chronic diseases. Mammalian cells have evolved elaborate mechanisms for restoring redox homeostasis and resolving acute inflammatory responses. One prominent mechanism is that of inducing the expression of antioxidant, anti-inflammatory and other cytoprotective proteins, while also suppressing the production of pro-inflammatory mediators, through the activation of transcription factor nuclear factor-erythroid 2 p45-related factor 2 (NRF2). At homeostatic conditions, NRF2 is a short-lived protein, which avidly binds to Kelch-like ECH-associated protein 1 (KEAP1). KEAP1 functions as (i) a substrate adaptor for a Cullin 3 (CUL3)-based E3 ubiquitin ligase that targets NRF2 for ubiquitination and proteasomal degradation, and (ii) a cysteine-based sensor for a myriad of physiological and pharmacological NRF2 activators. Here, we review the intricate molecular mechanisms by which KEAP1 senses electrophiles and oxidants. Chemical modification of specific cysteine sensors of KEAP1 results in loss of NRF2-repressor function and alterations in the expression of NRF2-target genes that encode large networks of diverse proteins, which collectively restore redox balance and resolve inflammation, thus ensuring a comprehensive cytoprotection. We focus on the cyclic cyanoenones, the most potent NRF2 activators, some of which are currently in clinical trials for various pathologies characterized by redox imbalance and inflammation.
Keywords: KEAP1; NRF2; anti-inflammatory; antioxidant; cysteine; redox.
Conflict of interest statement
A.T.D-K. is a member of the Scientific Advisory Board of Evgen Pharma and a consultant for Aclipse Therapeutics and Vividion Therapeutics.
https://pubmed.ncbi.nlm.nih.gov/32574549/
Vividion Therapuetics files for $100M IPO
Jun. 25, 2021
Roche Holding AG (RHHBY)By: Jonathan M Block, SA News Editor
Precision cancer and immune disorders focused Vividion Therapeutics has filed for a $100M IPO on the Nasdaq under the tickeR "VVID"
The per share price range and other financial details have yet to be disclosed.
J.P. Morgan, BofA Securities, and Jefferies are acting as joint book-runners.
Yesterday, Vividion received a milestone payment from Roche (OTCQX:RHHBY) for a collaboration on an oncology target. Last year, the two companies inked a deal that included a $135 upfront payment to Vividion for discovery and development of programs addressing a range of oncology and immunology targets.
Vividion's lead programs focus on transcription factor NRF2 for the potential treatment of NRF2 mutant cancers, as well as inflammatory diseases, such as irritable bowel disease and chronic kidney disease.
Perfectly poised.....and so fingers crossed for some stellar news....Gla ;-)
Looks like nervous selling, maybe people assuming something is up because it's taking so long.
Personally I don't necessarily think that's the case, we're still within the expected timescale.
Would like to know why it's taking them so long though!
Yep, was in the CEO's report in the final results RNS.
And
A further assessment, by the DMC, of unblinded data from the first 100 randomised patients, for safety and futility, will be performed imminently and will be announced in the coming weeks. The trial sponsor (University of Dundee/NHS Tayside) are cleaning the trial data and finalising the statistical basis for performing the analysis, and the output will be provided to the DMC for review shortly. The DMC assessment of futility will consider whether there is sufficient evidence of clinical improvement in the treatment arm compared with placebo to justify continuation of the trial.
We expect to be able to announce the DMC conclusions later this month in line with previous guidance as to timing thereof.
Jerichnoman - many thanks! I was focusing on the recent Annual Report and couldn't find anything in there confirming timelines.
Appreciated
Rns dated 17th April.
Dr Huw Jones CEO of Evgen commented: "We are pleased to note these findings from Johns Hopkins University. If the data continue to demonstrate efficacy after peer review, they underpin and support the hypothesis we are testing with the University of Dundee in the STAR COVID-19 clinical study. We anticipate receiving the outcome of the interim analysis of the first 100 patients completing the study during this second quarter of 2021."
Hi - I have just been going through various company announcements - can anyone please share with me where Evgen is saying that update/Covid results are due in Q2 (i.e. by the end of this month).
Really appreciated! Many thanks
Will let sell upto 300k before nt.
Tight spread, get the feeling Mms trying to suppress the market rather than make one.
Nearly there....don't bottle it now!! ( note to myself)
SFX-01 Covid results due imminently yet its very quiet. The calm before the storm maybe?
Buys showing as sells, the recent 7.60 trades are buys. we will end up blue today...imo
Just a reminder why we are waiting patiently.
However, the scientific evidence for sulforaphane and SFX-01 as a potent Nrf2 activator is compelling, and the clinical belief in Nrf2 activation as a therapeutic strategy is affirmed by the endorsement of our clinical investigator partners, who wish to test SFX-01 in various diseases where Nrf2 activation is important. We therefore remain committed to the on-going clinical development of SFX-01 both in breast cancer, and in supporting trials in a range of other diseases which may benefit from Nrf2 up-regulation".
"We therefore move forward with the confidence that clinical success will ultimately prevail and we will, at that point, see a major ground shift in the Company's valuation. Between now and that point we will focus on delivering our development plan; the fundamentals that are needed to underpin sustainable share price growth and ultimately deliver the undoubted potential of SFX-01".
yes typical Aim but ''very'' typical Evg and i say that as someone invested here.
Fingers crossed it all means nothing in the overall scheme of things come trial results day
Lost all of today’s gains ...
Typical AIM
Yep, it would be nice to think that Prof Chalmers was allowing his researchers, Phd students and friends and families to fill their boots because of encoraging data, although personally i would want to see a significant increase in volume that might suggest that good news is leaking, to be certain....Watch this Space...all bodes well. Gla holders ;-)
Some good buys in the last few days ...
But still basement prices , so let’s see where we go from here